CFTR modulators | Page 4 | European Cystic Fibrosis Society (ECFS)

Pregnancy outcomes in women with cystic fibrosis and poor pulmonary function

Building global development strategies for cf therapeutics during a transitional cftr modulator era

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

Amplifiers co-translationally enhance CFTR biosynthesis via PCBP1-mediated regulation of CFTR mRNA

Females with Cystic Fibrosis have a larger decrease in sweat chloride in response to lumacaftor/ivacaftor compared to males

Speeding up access to new drugs for Cystic Fibrosis: Considerations for clinical trial design and delivery

R560S: a class II CFTR mutation that is not rescued by current modulators

Measured fetal and neonatal exposure to Lumacaftor and Ivacaftor during pregnancy and while breastfeeding

Drugs during pregnancy and breast feeding in women diagnosed with Cystic Fibrosis – an update

Retrospective observational study of French patients with cystic fibrosis and a Gly551Asp-CFTR mutation after 1 and 2 years of treatment with ivacaftor in a real-world setting

first
previous
1
2
3
4
5
next
last